In response to findings from preclinical models, a phase 1 clinical trial (NL72549.056.20) was conducted to evaluate the impact of the SCD inhibitor YTX-7739 on PD using a randomized, double-blind, placebo-controlled design. The gene discussed is SCD; the disease is Parkinson disease.